Literature DB >> 16527559

Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach?

Philippe E Spiess1, Wassim Kassouf, Gordon Brown, Ralph Highshaw, Xuemei Wang, Kim-Anh Do, Ashish M Kamat, Bogdan Czerniak, Colin P N Dinney, H Barton Grossman.   

Abstract

OBJECTIVES: To compare treatment-related outcomes of immediate and staged urethrectomy in patients at high risk of urethral recurrence.
METHODS: We retrospectively identified 76 male patients with cystectomy for transitional cell carcinoma of the bladder who had undergone urethrectomy in the absence of established urethral recurrence. Concomitant cystoprostatectomy and urethrectomy was performed in 57 patients and staged urethrectomy in 19 patients. The criteria for staged urethrectomy were the presence of a positive urethral margin or established transitional cell carcinoma of the urethra in the cystectomy specimen. The mean interval from cystectomy to staged urethrectomy was 4.7 months (range 1.4 to 14).
RESULTS: The most common pathologic finding of the urethrectomy specimens was prostatic duct involvement (31.6%) in the immediate urethrectomy group and Stage pT0 in the delayed urethrectomy group (73.7%). No statistically significant difference in disease-specific survival was noted between the immediate and staged groups (P = 0.14). Similarly, no difference was noted in postoperative complication rates or total operative blood loss (P = 0.77 and P = 0.64, respectively). However, a slight benefit for immediate urethrectomy was noted in the total duration of hospitalization (P = 0.01). The presence of local or distant recurrence was a predictor of disease-specific survival (P = 0.02 and P = 0.02, respectively).
CONCLUSIONS: Immediate and staged urethrectomy appear to be similar in surgical morbidity and disease-specific survival. A benefit was noted for the immediate group in the total duration of hospitalization. The development of local or distant recurrence was a predictor of poor survival.

Entities:  

Mesh:

Year:  2006        PMID: 16527559     DOI: 10.1016/j.urology.2005.09.043

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

1.  Urethrectomy following cystectomy for bladder cancer in men: practice patterns and impact on survival.

Authors:  Jason L Nelles; Badrinath R Konety; Christopher Saigal; Jennifer Pace; Julie Lai
Journal:  J Urol       Date:  2008-09-17       Impact factor: 7.450

2.  Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study.

Authors:  Ekaterina Laukhtina; Axelle Boehm; Benoit Peyronnet; Carlo Andrea Bravi; Jose Batista Da Costa; Francesco Soria; David D'Andrea; Pawel Rajwa; Fahad Quhal; Takafumi Yanagisawa; Frederik König; Hadi Mostafaei; Dmitry Enikeev; Alexandre Ingels; Gregory Verhoest; Frederiek D'Hondt; Alexandre Mottrie; Steven Joniau; Hendrik Van Poppel; Alexandre de la Taille; Karim Bensalah; Franck Bruyère; Shahrokh F Shariat; Benjamin Pradere
Journal:  World J Urol       Date:  2022-05-20       Impact factor: 3.661

3.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

4.  New therapeutic targets in the management of urothelial carcinoma of the bladder.

Authors:  Einar F Sverrisson; Patrick N Espiritu; Philippe E Spiess
Journal:  Res Rep Urol       Date:  2013-03-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.